Clinical Trial Update: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for QLS-111 in combination with a prostaglandin analogue for open-angle glaucoma and ocular hypertension; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• QLS-111 (QLS-111)

Snippet

Sponsor: Qlaris Bio, Inc. | Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Phase 2 | Status: COMPLETED